Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
- 주제(키워드) Clinical trial , ctDNA , HER2 positive , Metastatic breast cancer , Trastuzumab biosimilar
- 등재 SCIE, SCOPUS
- OA유형 Green Published, gold
- 발행기관 Churchill Livingstone
- 발행년도 2022
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000194638
- 본문언어 영어
- Published As https://doi.org/10.1016/j.breast.2022.08.002
- PubMed https://pubmed.ncbi.nlm.nih.gov/36029565
초록/요약
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies. © 2022 The Authors
more